Genomate Health

We’re thrilled to have Ioana S., our Chief of Staff, take the stage at Plug and Play Tech Center’s Silicon Valley Summit ????

Hello Beautiful Switzerland, Hello, Charming Basel, ? I am excited to meet friends in Switzerland at the Swiss Oncology and Hematology Congress 2024 in Basel. Thank you, SAKK Swiss Group for Clinical Cancer Research, for the kind invitation. I am excited to discuss how to implement computer-assisted precision oncology in clinical practice and clinical research. The time has come to overcome the complexity of cancer biology with the power of computational methods and AI. Exciting times. See you soon! ? #Genomate #SAKK #SOHC2024 #precisiononcology #artificialintelligence

We’re thrilled to announce that our founder and CEO, Istvan Petak, MD, PhD, will be a featured speaker today (from 13:45 to 14:35 CET) at the Open session of the SAKK Swiss Group for Clinical Cancer Research sessions during their semi-annual meeting. This event is part of the #SOHC Swiss Oncology and Hematology Congress 2024. Dr. Petak will share insights into how AI and computational methods, like Genomate, are revolutionizing precision oncology—ensuring every cancer patient gets the most effective, personalized treatment. Don’t miss out on the full program: https://lnkd.in/ekfnRc88 #SAKK #SOHC2024 #Oncology #Hematology #MedicalConference #Networking

How do we move beyond one-size-fits-all cancer treatments to truly personalized care? This question has driven decades of innovation in precision oncology—and now, the answer is here. In this Labroots webinar, our founder, Istvan Petak, MD, PhD, explores how computational reasoning is revolutionizing cancer treatment by selecting N-of-1 therapies tailored to each patient’s unique molecular profile. Watch the full recording here: https://lnkd.in/dygdG9zY

?????????????? ?????????????????? ???? ?????? ???????? ???????????? ????????-???????????? ??????????????! Computational methods and artificial intelligence (AI/ML) are revolutionizing cancer research and patient care. The Research Group Developmental Therapeutics (PG DT), chaired by Anastasios Stathis, Prof MD, is excited to announce that Istvan Petak, MD, PhD, adjunct professor at the Department of Pharmaceutical Sciences at the University of Illinois Chicago at Chicago, Széchenyi István University Gy?r and a lecturer at #Semmelweis University, Budapest and founder of Genomate Health (Cambridge, MA, USA), will talk about the “Implementation of computer-assisted precision oncology in the clinical practice and clinical research” on November 21, 2024, from 13:45 to 14:35 CET in the Room Mexiko. Don’t miss out on the full program, featuring 16 different #SAKK sessions! ?? ?????????? ?????? ?????? ???????? ?????????????? ???????? https://lnkd.in/ekfnRc88 We look forward to seeing you at the #SAKK winter semi-annual meeting, part of the #SOHC Swiss Oncology and Hematology Congress 2024! ?? #SAKK #SOHC2024 #Oncology #Hematology #MedicalConference #Networking

While the incidence and mortality of stomach cancer have significantly declined worldwide over the past five decades, it remains a global health challenge - the fifth most common cancer and the fourth leading cause of cancer-related deaths globally. Each year, hundreds of thousands are affected, highlighting the urgent need for awareness, early detection, and innovative treatments. At Genomate Health, we’re working to change the landscape of gastric cancer treatment through precision oncology. By analyzing each patient’s unique genetic and molecular profile, we help clinicians personalize treatment plans, ensuring the best possible care for gastric cancer patients. This #GastricCancerAwarenessMonth, let’s come together to raise awareness, support those affected, and continue pushing for better diagnostic tools and treatments. #StomachCancer #PrecisionOncology #GenomateHealth

This past week, our founder and CEO, Istvan Petak, MD, PhD, had the incredible opportunity to visit Vietnam and connect with the nation’s leading minds in oncology. From presenting the future of precision oncology to exchanging insights with esteemed experts, it has been a memorable journey. Dr. Petak shared insights on the future of precision oncology and engaged in inspiring discussions with top experts and healthcare leaders. The enthusiasm of the Vietnamese oncology community to make personalized cancer care accessible to patients reaffirms the vision we share for transforming cancer treatment in the region. A special thank you to our incredible partners at Digosys. Your hard work and commitment were essential in making this week possible, and we are grateful for your support! We look forward to building on this momentum, working together with our partners in Vietnam to drive innovation and make a lasting difference in cancer care. #GenomateHealth #PrecisionOncology #Vietnam

Carcinoid cancer, a rare and often slow-growing type of neuroendocrine tumor, can develop in various parts of the body, commonly affecting the gastrointestinal tract and lungs. Its subtle symptoms often make early detection challenging, underscoring the importance of awareness and proactive health screenings. At Genomate Health, we are committed to advancing precision oncology to support clinicians in diagnosing and treating even the rarest cancers with accuracy. By leveraging each patient’s unique genetic and molecular profile, our solutions aim to guide more effective, personalized treatments ??? #CarcinoidCancerAwarenessMonth #RareCancers #PrecisionOncology #GenomateHealth

Event season is in full swing, and our team is on the move!?Our Science Team participated in the 13th Congress of the Hungarian Society of Medical Oncology (MKOT). Staying true to the event’s motto, we showcased how AI can reshape the field of oncology with two impactful presentations. The program was filled with fantastic insights, giving us new ideas and collaborations to build upon as we advance in precision oncology. Here’s a look at our team’s contributions: 1?? Real-world performance of the digital drug-assignment system for precision oncology in lung cancer – highlighting the clinical effectiveness of our model in predicting targeted therapy outcomes (A Dirner et al. Journal of Clinical Oncology 42 (16_suppl), e13590-e13590) 2?? Algorithmic precision in immune checkpoint therapy response prediction for lung cancer – evaluating the model's accuracy in predicting response to immune checkpoint therapies (B Vodicska et al. Journal of Clinical Oncology 42 (16_suppl), 8523-8523) A huge thank you to MKOT for organizing this event and to all participants for the engaging discussions. We’re excited to bring these learnings forward as we continue to innovate in precision oncology. #GenomateHealth #PrecisionOncology #MKOT #LungCancer

Event season is in full swing, and our team is on the move! Our colleagues, Peter Filotas and Kitti Morvai-Sztancs, were at ME.E.T. CEE—a full day dedicated to networking with investors, startup founders, and key players from across the region. ME.E.T. CEE brought together an incredible community of innovators, and we were thrilled to connect, collaborate, and explore new opportunities in precision oncology and digital health. Thank you to all who made the event such a success—we’re energized by the discussions and look forward to advancing healthcare innovation in the CEE region and beyond! #GenomateHealth #MEETCEE #PrecisionOncology #HealthcareInnovation